This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Franciosa, J. A. Articles by Cohn, J. N. Search for Related Content PubMed PubMed Citation Articles by Franciosa, J. A. Articles by Cohn, J. N.

Circulation, Vol 63, 652-657, Copyright © 1981 by American Heart Association

ARTICLES

Effects of minoxidil on hemodynamics in patients with congestive heart failure

JA Franciosa and JN Cohn

Vasodilators used in chronic congestive heart failure are not optimal in that nitrates are predominant venodilators, prazosin is associated with tolerance development, and hydralazine produces chronic toxicity. Therefore, we studied the acute hemodynamic effects of a single dose of minoxidil in 18 patients with chronic left ventricular failure caused by ischemic or primary cardiomyopathy. Peak effects were observed 5 hours after single oral doses of minoxidil, averaging 15.3 +/- 1.4 mg (SEM). Heart rate rose slightly, from 85.4 +/- 2.9 to 90.9 +/- 3.2 beats/min, after minoxidil (p less than 0.02) and mean arterial pressure fell slightly, from 88.0 +/- 2.3 to 84.9 +/- 2.5 mm Hg (p less than 0.05). Cardiac index increased from 2.34 +/- 0.l4 to 2.95 +/- 0.29 l/min/m2 after minoxidil (p less than 0.02) and systemic vascular resistance fell from 19.6 +/- 1.5 to 15.0 +/- 1.3 units (p less than 0.01). Minoxidil did not affect right atrial, pulmonary arterial and pulmonary wedge pressures. Hemodynamic effects of minoxidil persisted for at least 8 hours after a single dose. Minoxidil appears to be an effective arterial dilating agent in patients with heart failure and resembles hydralazine in its actions. Because of its potency, prolonged duration of action and relatively low toxicity, minoxidil may be a useful vasodilator for heart failure. However, its long-term effect must be further evaluated.

This article has been cited by other articles:

				M. R. Shah, V. Hasselblad, S. S. Stinnett, J. M. Kramer, S. Grossman, M. Gheorghiade, K. F. Adams Jr., K. Swedberg, R. M. Califf, and C. M. O'Connor Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure Eur J Heart Fail, June 1, 2002; 4(3): 297 - 304. [Abstract] [Full Text] [PDF]

				D. L. Groden Vasodilator Therapy for Congestive Heart Failure: Lessons From Mortality Trials Arch Intern Med, February 22, 1993; 153(4): 445 - 454. [Abstract] [PDF]

				M. A. Munger, S. F. Gardner, and R. C. Jarvis Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331. [Abstract] [PDF]

				M. PACKER Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards Ann Intern Med, August 1, 1985; 103(2): 258 - 270. [Abstract] [PDF]